Zyversa Therapeutics Inc (ZVSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -24,274 | -4,468 | -2,257 | -9,413 | -7,992 |
| Depreciation Amortization | N/A | N/A | N/A | 7 | 7 |
| Income taxes - deferred | -852 | N/A | N/A | 7 | 10 |
| Accounts payable and accrued liabilities | 371 | 56 | 191 | 751 | 676 |
| Other Working Capital | 1,331 | 833 | 331 | 930 | 1,038 |
| Other Operating Activity | 18,722 | 286 | -38 | 160 | -44 |
| Operating Cash Flow | $-4,701 | $-3,294 | $-1,772 | $-7,560 | $-6,305 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | N/A | 1,354 | N/A |
| Common Stock Issued | 2,052 | 2,000 | 2,000 | 5,187 | 3,501 |
| Other Financing Activity | 1,646 | -165 | -147 | -588 | -210 |
| Financing Cash Flow | $3,698 | $1,835 | $1,853 | $5,953 | $3,290 |
| Beginning Cash Position | 1,531 | 1,531 | 1,531 | 3,138 | 3,138 |
| End Cash Position | 528 | 72 | 1,612 | 1,531 | 123 |
| Net Cash Flow | $-1,003 | $-1,459 | $81 | $-1,607 | $-3,015 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,701 | -3,294 | -1,772 | -7,560 | -6,305 |
| Free Cash Flow | -4,701 | -3,294 | -1,772 | -7,560 | -6,305 |